Results 231 to 240 of about 81,076 (308)

Combination of Janus kinase inhibitor and biologic for recalcitrant severe atopic dermatitis. [PDF]

J Eur Acad Dermatol Venereol
De Greef A, Baeck M.
europepmc   +1 more source

Inflammatory and Immunological Basis of Periodontal Diseases

Journal of Periodontal Research, EarlyView.
The periodontal lesion emerges as an evolving immunological battlefield, where host–microbiome interactions, dysregulated immune responses, fragile resolution mechanisms, and inflammophilic dysbiosis converge to shift the balance from homeostasis to unrestrained tissue destruction.
Giacomo Baima, Marion Arce, Mario Romandini, Thomas Van Dyke   +3 more
wiley   +1 more source

Systemic Treatment with the Janus Kinase Inhibitor Baricitinib in Ocular Chronic Graft-versus-Host Disease. [PDF]

Ophthalmol Sci
McManus T, Holtzman NG, Zhao A, Cousineau-Krieger C, Vitale S, FitzGibbon EJ, Payne D, Newgen J, Igbinosun C, Im AP, Peer C, Figg WD, Cowen EW, Mays JW, Pavletic S, Magone MT.   +15 more
europepmc   +1 more source

Guard cell photorespiration controls stomata behavior and development

New Phytologist, EarlyView.
Summary Photorespiration is traditionally viewed as a limitation to photosynthetic efficiency. However, it is mandatory for safeguarding the Calvin–Benson–Bassham cycle from inhibitory byproducts through Rubisco‐mediated oxidative misfire and is tightly integrated with primary metabolism.
Hu Sun, Inken Thiemann, Nils Schmidt, Johannes Kromdijk, Tracy Lawson, Martin Hagemann, Stefan Timm   +6 more
wiley   +1 more source

Preclinical and clinical evaluation of the Janus Kinase inhibitor ruxolitinib in multiple myeloma. [PDF]

Oncotarget
Del Dosso A, Tadevosyan E, Berenson JR.
europepmc   +1 more source

Dupilumab Reduces Pruritus in Twins With Sjögren–Larsson Syndrome

Pediatric Dermatology, EarlyView.
ABSTRACT Sjögren–Larsson Syndrome (SLS), now termed ALDH3A2‐syndromic epidermal differentiation disorder (sEDD), is a rare genetic disorder marked by thickened skin, spasticity, and intellectual disability. Intractable pruritus is a nearly universal and debilitating feature of SLS that remains poorly managed by current therapies. We describe 4‐year‐old
Kennedy Gallagher, Rame Yousif, Kathryn Hummel, Amy S. Paller   +3 more
wiley   +1 more source

Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphoma. [PDF]

Leuk Lymphoma
Horwitz SM, Feldman TA, Ye JC, Khodadoust MS, Munoz J, Hamlin PA, Kim YH, Wilcox RA, Patel MR, Coffey G, Innes A, Betz A, Holland J, Guzman CB, Smith SM.   +14 more
europepmc   +1 more source

Fatal Chronic Varicella‐Zoster Viral Infection in a Young Man With Chediak–Higashi Syndrome

Pediatric Dermatology, EarlyView.
ABSTRACT Chediak–Higashi syndrome (CHS) is a rare autosomal recessive primary immunodeficiency characterized by partial oculocutaneous albinism, neurologic involvement, and a predisposition to severe infections. Patients are particularly susceptible to developing hemophagocytic lymphohistiocytosis (HLH), which significantly worsens prognosis. We report
Albane Badet, Clément Pruvot, Zoé Manssens, Wadih Abou‐Chahla, Sébastien Buche   +4 more
wiley   +1 more source

Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies [PDF]

, 2014
DiPersio, John F, et al,
core   +1 more source